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Effect of Natriuretic Peptide–Guided Therapy
on Hospitalization or Cardiovascular Mortality in High-Risk
PatientsWith Heart Failure and Reduced Ejection Fraction
A Randomized Clinical Trial
G. Michael Felker, MD, MHS; Kevin J. Anstrom, PhD; Kirkwood F. Adams, MD; Justin A. Ezekowitz, MBBCh, MSc; Mona Fiuzat, PhD;
Nancy Houston-Miller, RN, BSN; James L. Januzzi Jr, MD; Daniel B. Mark, MD, MPH; Ileana L. Piña, MD, MPH;
Gayle Passmore, PMP; David J. Whellan, MD, MHS; Hongqiu Yang, PhD; Lawton S. Cooper, MD, MPH; Eric S. Leifer, PhD;
Patrice Desvigne-Nickens, MD; Christopher M. O’Connor, MD
IMPORTANCE The natriuretic peptides are biochemical markers of heart failure (HF) severity
and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy
based on natriuretic peptide levels (“guided therapy”) with inconsistent results.
OBJECTIVE To determine whether an amino-terminal pro–B-type natriuretic peptide
(NT-proBNP)–guided treatment strategy improves clinical outcomes vs usual care in high-risk
patients with HF and reduced ejection fraction (HFrEF).
DESIGN, SETTINGS, AND PARTICIPANTS The Guiding Evidence Based Therapy Using Biomarker
Intensified Treatment in Heart Failure (GUIDE-IT) study was a randomizedmulticenter clinical
trial conducted between January 16, 2013, and September 20, 2016, at 45 clinical sites in the
United States and Canada. This study planned to randomize 1100 patients with HFrEF
(ejection fraction40%), elevated natriuretic peptide levels within the prior 30 days, and a
history of a prior HF event (HF hospitalization or equivalent) to either an NT-proBNP–guided
strategy or usual care.
INTERVENTIONS Patients were randomized to either an NT-proBNP–guided strategy or usual
care. Patients randomized to the guided strategy (n = 446) had HF therapy titrated with the
goal of achieving a target NT-proBNP of less than 1000 pg/mL. Patients randomized to usual
care (n = 448) had HF care in accordance with published guidelines, with emphasis on
titration of proven neurohormonal therapies for HF. Serial measurement of NT-proBNP
testing was discouraged in the usual care group.
MAIN OUTCOMES ANDMEASURES The primary end pointwas the composite of time-to-first HF
hospitalization or cardiovascularmortality. Prespecified secondary end points included all-cause
mortality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular
reasons, the individual components on the primary end point, and adverse events.
RESULTS The data and safety monitoring board recommended stopping the study for futility
when 894 (median age, 63 years; 286 [32%] women) of the planned 1100 patients had been
enrolled with follow-up for a median of 15 months. The primary end point occurred in 164
patients (37%) in the biomarker-guided group and 164 patients (37%) in the usual care group
(adjusted hazard ratio [HR], 0.98; 95% CI, 0.79-1.22; P = .88). Cardiovascular mortality was
12% (n = 53) in the biomarker-guided group and 13% (n = 57) in the usual care group
(HR, 0.94; (95% CI, 0.65-1.37; P = .75). None of the secondary end points nor the decreases in
the NT-proBNP levels achieved differed significantly between groups.
CONCLUSIONSANDRELEVANCE In high-risk patientswithHFrEF, a strategy ofNT-proBNP–
guided therapywas notmore effective than a usual care strategy in improving outcomes.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01685840
JAMA. 2017;318(8):713-720. doi:10.1001/jama.2017.10565
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E vidence-based therapies targetingneurohormonal acti-vation significantly improve outcomes in patients withheart failure (HF). Nevertheless, available data suggest
thatmanypatients inclinicalpracticeareeithernot treatedwith
these agents or are treated with lower than recommended
doses.1,2 The natriuretic peptides, specifically B-type natri-
uretic peptide (BNP) and amino-terminal pro–B-type natri-
uretic peptide (NT-proBNP), are biomarkers that reflect HF se-
verity and are significantly associated with adverse outcomes
in HF.3,4 These markers decline in response to the use of
guideline-recommended HF therapies, and rising levels por-
tendapoorprognosis.5Theseobservationaldatahave ledto the
hypothesis thatserialmeasurementsofnatriureticpeptidesmay
be used to guide titration of long-termmedical therapy in HF.
Previous clinical trials of varying size and design have
tested this hypothesis over the last 2 decades with mixed
results.6-11 These studies have generally been limited by their
small size andalsoby significantheterogeneity between stud-
ies. Several meta-analyses have suggested substantial ben-
efits with this approach, but no individual study has been of
sufficient power to be definitive.12,13 In light of this uncer-
tainty, current guidelines do not recommend the use of serial
measurements of natriuretic peptides to guide titration of
HF therapy.14,15 The Guiding Evidence Based Therapy Using
Biomarker Intensified Treatment in Heart Failure (GUIDE-IT)
multicenter randomized clinical trial was designed to evalu-
ate the efficacy of an NT-proBNP–guided HF treatment strat-
egy compared with optimal medical therapy alone in high-
risk patients with HF and reduced ejection fraction (HFrEF).
Methods
Study Design
Thedetails of the rationale anddesign for this studyhavebeen
published previously.16 The study protocol, including the sta-
tisticalanalysisplan, isprovided intheeMaterial inSupplement
1. The studywas approved by the institutional reviewboard at
each study site, and all participants provided written in-
formed consent. An independent data and safety monitoring
board(DSMB)appointedbytheNationalHeart,Lung,andBlood
Institute (NHLBI)monitored study conduct andpatient safety.
To maximize adherence to the study protocol, an adherence
committee reviewed episodes inwhichHF therapywas not ti-
trateddespiteNT-proBNPvaluesbeingabovethetargetandpro-
vided general feedback to the executive committee and the
study sites (including study site score cards indicating cumu-
lative site performance with regard to protocol adherence) on
a regular basis. The adherence committee had a stepped ap-
proached for siteswith consistentlypoorperformance, includ-
ing contact from the coordinating center and escalation to the
executive committee to reinforce studygoals and site training.
Study Participants
Patientswereeligible for enrollment if theyhadchronicHFrEF
with an ejection fraction of 40%or less, a history of a priorHF
event (hospitalization forHF, emergencydepartment visit for
HF, or outpatient treatmentwith intravenousdiuretics forHF)
within the prior 12 months, and an NT-proBNP level of more
than 2000 pg/mL or BNP ofmore than 400 pg/mLwithin the
prior 30days.Patientswereexcluded if theyhadanacutecoro-
nary syndromeor revascularizationprocedurewithin theprior
30 days, cardiac resynchronization therapywithin the prior 3
months, end-stage renal disease, or anticipated heart trans-
plantormechanical cardiac supportwithin thenext 12months.
In accordance with National Institutes of Health policy,
patient-reportedrace/ethnicity informationwascollectedusing
fixed categories.
Randomization and Treatment Assignments
Enrolled patients were randomized in a 1:1 fashion using com-
puter-generated random numbers using a simple randomiza-
tion design with no restrictions to either the NT-proBNP–
guided therapy strategy or usual care. Given the nature of
the study intervention, treatmentassignmentwasnotblinded.
For patients randomized to the NT-proBNP-guided strategy,
clinicians were instructed to titrate HF therapy to target an
NT-proBNP level of less than 1000 pg/mL. Specific adjust-
ments of therapy for individual patientswere at the discretion
of the treating physician, but sites were encouraged to priori-
tize titration of neurohormonal antagonists over diuretics un-
less there was clinical evidence of congestion or volume over-
load.PatientsrandomizedtotheNT-proBNP–guidedgroupused
local laboratory NT-proBNPmeasurements to make decisions
about titration of HF therapy. All patients in either group also
hadblindedNT-proBNPconcentrationsmeasuredinacore labo-
ratory at each study visit. For patients in either group, investi-
gators were provided with the most recent American Heart
Association (AHA)/AmericanCollegeofCardiology (ACC)prac-
tice guidelines for the management of HF and specific infor-
mationontargetdosesofprovenmedical therapies.Afteran ini-
tial visit at 2 and 6 weeks, visits occurred every 3 months
throughout the remainder of the study. After therapy adjust-
mentforHF(whetherdrivenbyNT-proBNPlevelsorclinical rea-
sons), patients had a 2-week follow-up visit for reassessment.
Study Outcomes
The primary outcome was a composite of time-to-first HF
hospitalizationordeath fromcardiovascular causes. Prespeci-
fied secondary end points included all-cause mortality,
total hospitalizations for HF, days alive and not hospitalized
for cardiovascular reasons, the individual components on
Key Points
Question Does a strategy of titrating therapy to a specific
amino-terminal pro–B-type natriuretic peptide (NT-proBNP) target
improve clinical outcomes in high-risk patients with heart failure
and reduced ejection fraction?
Findings In this randomized clinical trial including 894 adults,
a strategy of NT-proBNP–guided therapy compared with usual care
did not significantly improve time to first hospitalization or
cardiovascular mortality (hazard ratio, 0.98).
Meaning These findingsdonot supportNT-proBNP–guided therapy
formanagementof heart failurewith reducedejection fraction.
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the primary end point, health-related quality of life, resource
utilization, costs, cost-effectiveness, and safety.Results of the
economic and quality-of-life analyses are not reported in this
article.Adjudicationof all deathsandhospitalizationswascar-
ried out by a blinded clinical end point committee according
to prespecified criteria.Wepredefined4 adverse events of in-
terest thatmight be anticipated tooccurmore frequentlywith
more aggressive HF treatment: symptomatic hypotension,
symptomatic bradycardia, hyperkalemia, and worsening re-
nal function.
Statistical Analysis
A total sample size of 1100 patients (550 per group) was ex-
pected to provide approximately 90%power to detect a differ-
ence in theprimary endpointwith anassumed type I error rate
of .05, 2-sided.We estimated that the annual event rate for the
composite endpointwouldbe40% in theusual care group.We
targeted a 20%decrease in the primary end point at 12months
for the biomarker-guided group in the sample size calculation,
basedontherecognitionthat this treatmenteffectwouldbecon-
sistent with other effective HF therapies that have been incor-
porated into clinical practice.17 According to protocol, all pa-
tientsweretobefollowedupforbetween12and24monthsafter
randomization (the last patient enrolled to be followed up for
12 months). For the analysis of the primary end point, the ad-
justed hazard ratio (HR) would be adjusted for 5 prespecified
baselinecovariates—age,sex,ejectionfraction,NT-proBNPlevel,
and the presence of diabetes mellitus—within the Cox regres-
sion model. For missing baseline categorical variables, we
imputed the most common value. For missing baseline
NT-proBNPvalues,weused theNT-proBNPvalue fromscreen-
ing. For missing baseline ejection fraction values, we imputed
thepopulationmedian.Wealsoperformedtheprimaryendpoint
analysiswithsiteasa randomeffectasasensitivityanalysis.We
tested for heterogeneity of effect on the primary end point by
testing for interactions within a number of subgroups defined
bydemographics andbaseline characteristics (see Supplement
2).Asubgroupanalysisbasedonage(≥75yearsvs<75years)was
prespecified based on prior data suggesting that biomarker-
guidedtherapywasmoreeffective inyoungerpatients.9Forsec-
ondary analyses, inverse probabilityweightingwas used to es-
timate mean days alive out of the hospital using the Bang-
Tsiatispartitionedestimator.18Thetotalnumberof recurrentHF
hospitalizations by treatment group was modeled using the
Andersen-Gill intensitymodel.19All analyseswerebasedonthe
principleof intentiontotreat.Allanalyseswereperformedusing
SAS version 9.4 (SAS Institute Inc). The threshold for statistical
significancewas2sidedwitha type Ierror rateof .05.Therewas
no adjustment performed formultiple comparisons; thus, sec-
ondary outcomeswere considered exploratory.
Results
Study Patients
A total of 894 patients were enrolled at 45 sites in the United
States and Canada between January 2013 and July 2016
(Figure 1). The groups were generally well balanced with re-
spect to baseline characteristics (Table 1). The study enrolled
patients with high-risk HF, as characterized by a low ejection
fraction (median, 25%), significantly elevated NT-proBNP
(median, 2653 pg/mL), and a history of prior HF hospitaliza-
tion (or equivalent) in the past year. Most patients were re-
ceiving recommendedpharmacological therapy for chronicHF
at baseline. Themedian follow-up time for all patients was 15
months. Missing data for the 5 prespecified adjustment co-
variates was rare (none for age or sex, 1 for diabetes mellitus,
14 for baseline NT-proBNP, and 12 for ejection fraction).
At the regularly scheduledDSMBmeetingon July8, 2016,
atwhich timeabout 50%ofplannedprimary endpoint events
hadoccurred, thestudymetprespecified inefficacycriteriaand
the DSMB made a recommendation to the NHLBI to discon-
tinue the study due to lack of efficacy evidence for the bio-
marker-guidedtreatmentgroupcomparedwithusual care.The
NHLBIaccepted this recommendationandenrollmentwasdis-
continuedafter894patientshadbeenenrolled (81%ofplanned
enrollment). Final studyvisits for all patients still activelypar-
ticipating in the trial were completed prior to database lock.
Medical Treatment by Strategy and Follow-up
Patients randomized to the biomarker-guided strategy had
a greater number of study clinic visits (median, 12 vs 10,
Wilcoxon P = .002) and more adjustments to HF therapy
(median, 6 vs 4, Wilcoxon P < .001) compared with patients
randomized to usual care. Over the course of the study, there
wasmodest intensificationofHF therapy inbothgroups,with-
out statistically significantdifferencesbetween those random-
ized to NT-proBNP-guided therapy or usual care (Table 2).
Study Outcomes
Thecompositeendpointof firsthospitalization forHFordeath
from a cardiovascular cause occurred in 164 patients (37%) in
Figure 1. Flow of Patients in the GUIDE-IT Triala
894 Randomizedb
446 Randomized to receive
biomarker-guided therapy
446 Received biomarker therapy
as randomized
448 Randomized to usual care
448 Received usual care as
randomized
397 Completed the study
114 Completed protocol
66 Died
200 Discontinued due to study
termination
17 Other (ventricular assistive
device, dialysis, or transplant)
404 Completed the study
119 Completed protocol
77 Died
197 Discontinued due to study
termination
11 Other (ventricular assistive
device, dialysis, or transplant)
49 Withdrawn
25 Lost to follow-up
17 Withdrew consent
7 Withdrawn by site investigator
44 Withdrawn
27 Lost to follow-up
14 Withdrew consent
3 Withdrawn by site investigator
446 Included in the primary analysis 448 Included in the primary analysis
a The number of patients screened for eligibility was not available.
b Patients who had study contact within 90 days prior to the study’s
termination are considered complete in this diagram.
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Table 2. Differences inMedical Therapy Over Time Between Treatment Groups
NT-ProBNP–Guided Group
(n = 446)
Usual Care Group
(n = 448)
P ValueaBaseline 12 Months Baseline 12 Months
Taking β-blocker, No. (%) 415 (93) 227 (91) 416 (93) 219 (91) .86
Mean dose achieved
(% of target dose)
33 48 35 45 .60
50% of target dose 152 (37) 136 (60) 139 (33) 125 (57) .97
100% of target dose 30 (7) 33 (15) 26 (6) 25 (11) .31
Taking ACE/ARB, No. (%) 342 (77) 187 (75) 333 (74) 172 (71) .63
Mean dose achieved
(% of target dose)
41 55 43 53 .35
50% of target dose 140 (41) 95 (51) 135 (41) 85 (49) .74
100% of target dose 59 (17) 58 (31) 67 (20) 46 (27) .11
Taking MRA, No. (%) 223 (50) 136 (54) 217 (48) 126 (52) >.99
Mean dose achieved
(% of target dose)
98 115 94 103 .29
50% of target dose 219 (98) 135 (99) 216 (100) 125 (99) .42
100% of target dose 170 (76) 116 (85) 163 (75) 94 (75) .06
Loop diuretics, mean dose
(mg furosemide equivalents)
77 86 76 77 .26
Abbreviations: ACE/ARB,
angiotensin-converting
enzyme/angiotensin II receptor
blocker; MRA, mineralocorticoid
receptor antagonist; NT-proBNP,
amino-terminal pro–B-type
natriuretic peptide.
a P value is for comparison of change
over time in NT–proBNP–guided
group vs change over time in usual
care group.
Table 1. Baseline Characteristics of the Study Population
Characteristic
NT-ProBNP–Guided Group
(n = 446)
Usual Care Group
(n = 448)
Age, median (IQR), y 62 (51-70) 64 (54-72)
Women, No. (%) 139 (31) 147 (33)
Race/ethnicity, No. (%)
White 230 (54) 260 (59)
Black 168 (39) 156 (35)
Other 35 (7) 26 (6)
Hispanic 30 (7) 28 (6)
Duration of HF, median (IQR), mo 12 (1-65) 16 (1-61)
Ejection fraction, median (IQR), % 24 (19-30) 25 (20-30)
NYHA class at enrollment, No. (%)
I 36 (8) 23 (5)
II 218 (50) 229 (52)
III 176 (40) 182 (41)
IV 8 (2) 9 (2)
Risk factors, No. (%)
Ischemic heart disease 203 (46) 244 (55)
Diabetes mellitus 198 (44) 212 (47)
Atrial fibrillation 162 (36) 196 (44)
Chronic kidney disease 161 (36) 169 (38)
Systolic BP, median (IQR), mm Hg 114 (102-128) 114 (101-128)
Heart rate, median (IQR), beats/min 77 (68-87) 76 (67-86)
NT-proBNP, median (IQR), pg/mL 2632 (1462-5235) 2668 (1481-5604)
Creatinine, median (IQR), mg/dL 1.3 (1.1-1.7) 1.3 (1.1-1.7)
Treatments
β-Blocker, No. (%) 415 (93) 416 (93)
ACE, angiotensin II receptor blocker,
or angiotensin receptor blocker
neprilysin inhibitor, No. (%)
345 (77) 339 (76)
Mineralocorticoid antagonist, No. (%) 223 (50) 217 (48)
Implantable cardioverter-defibrillator, No. (%) 182 (41) 178 (40)
Cardiac resynchronization therapy, No (%) 87 (20) 76 (17)
Abbreviations: ACE,
angiotensin-converting enzyme;
BP, blood pressure; HF, heart
failure; IQR, interquartile range;
NT-proBNP, amino-terminal
pro–B-type natriuretic peptide;
NYHA, New York Heart Association.
SI conversion factor: to convert
creatinine frommg/dL to μmol/L,
multiply values by 88.4.
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thebiomarker-guidedgroupand164patients (37%) in theusual
care groupwith 12-month Kaplan-Meier event rates of 33.8%
and36.0%, respectively,with a treatmentdifferenceof −2.2%
(95%CI, −9.1% to4.6%).After adjustment for prespecified co-
variates, the adjusted HR for the primary end point was 0.98
(95%CI, 0.79-1.22; P = .88) (Figure 2). These results were not
significantly changedby including site as a randomeffect (HR,
0.99; 95% CI, 0.79-1.23; P = .92). Data for all-causemortality,
cardiovascularmortality,HFhospitalization,andall-causehos-
pitalizationwerealsonot significantlydifferentbetween treat-
ment groups (Table 3). Death occurred in 66 patients (15%) in
the biomarker-guided group and 77 (17%) in the usual care
group. The 12-month Kaplan-Meier event rates for all-cause
mortalitywere9.8% for biomarker-guidedgroupand 14.1% in
the usual care group for a treatment difference of −4.3% (95%
CI, −8.9% to 0.3%). After adjustment for the prespecified co-
variates, theadjustedHRforall-causemortalitywas0.86 (95%
CI, 0.62-1.20; P = .37).
Table 3. Secondary Outcomes
NT-ProBNP-Guided
Group
Usual Care
Group Effect (95% CI) P Value
Mortality, No. (%) 66 (15) 77 (17) HR, 0.86 (0.62-1.20) .37
CV mortality, No. (%) 53 (12) 57 (13) HR, 0.94 (0.65-1.37) .75
Non-CV mortality, No. (%) 13 (3) 20 (5) HR, 0.66 (0.33-1.32) .24
First HF hospitalization, No. (%) 147 (33) 141 (32) HR, 1.04 (0.82-1.31) .76
Total HF hospitalizations, No. 350 277 HR, 1.29 (0.97-1.72) .08a
Days alive and not hospitalized for CV
reasons, mean (SD), d
581 (14.4) 562 (15.1) Mean difference, 19.26
(−21.58 to 60.10)
.36b
Abbreviations: CV, cardiovascular;
HF, heart failure; NT-proBNP,
amino-terminal pro–B-type
natriuretic peptide.
a Based on Andersen-Gill intensity
model.
b Based on Bang-Tsiatis partitioned
estimator.
Figure 2. Primary End Point (Heart Failure Hospitalization or Cardiovascular Mortality) and All-CauseMortality
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Therewasgenerallynoevidenceofheterogeneityof treat-
ment effect in a number of prespecified and post hoc sub-
groups (eFigure in Supplement 2). Changes in the concentra-
tions of NT-proBNP (based on blinded central core laboratory
data) decreasedover time inboth groups andwerenot signifi-
cantly different between groups; at 12 months, the median
NT-proBNP had decreased from a median of 2568 pg/mL to
1209pg/mL(53%decrease) in thebiomarker-guidedgroup,and
from a median of 2678 pg/mL to 1397 pg/mL (48% decrease)
in the usual care group (Figure 3). The proportion of patients
in both groups achieving the target value of NT-proBNP less
than 1000 pg/mL at 12 months was 46% for the biomarker-
guided group vs 40% for the usual care group (P = .21).
Adverse Events
Theratesof thepredefinedadverseeventsof interest (ie, symp-
tomatic hypotension, symptomatic bradycardia, hyperkale-
mia, and worsening renal function) were generally low and
similar between the groups (eTable in Supplement 2).
Discussion
The primary finding of this study is that in high-risk patients
with HFrEF, a strategy of guiding therapy based on concen-
trationsofNT-proBNPwasnotmoreeffective thanausual care
strategy in reducing the composite end point of time-to-first
HF hospitalization or cardiovascular death. Similarly not sig-
nificantly different results were seen in other clinical end
points. Although there were more adjustments to therapy in
the biomarker-guided group, neither doses of guideline-
directed medical therapy, the achieved NT-proBNP concen-
trations, nor clinical outcomeswere significantlydifferent be-
tween the treatment groups.
These results differ from other data, including a recent
comprehensive patient-levelmeta-analysis of data from2431
patients from 11 trials which showed a reduction in all-cause
mortality with natriuretic peptide-guided therapy compared
withusual care (HR,0.62).13Aconsistent featureofother stud-
ies inwhichnatriuretic peptide-guided therapywas shown to
be effectivewas thedifferential utilization of neurohormonal
therapies as well as a separation of achieved natriuretic pep-
tide concentrations between the 2 study groups. The up-
titration of medical therapy in the NT-proBNP group in this
study was substantially less than that seen in some smaller
studies of biomarker-guided therapy. For example, a random-
ized study of 278 patients in 8 Austrian hospitals achieved
100% of angiotensin-converting enzyme (ACE) inhibitor or
angiotensin II receptor blocker (ARB) target doses and 77%of
β-blocker target doses in patients randomized to receive
biomarker-guided therapy,whichwas accompaniedby a sub-
stantial reduction in HF events.10
Although it is challenging to compare across studies, the
achieved dosing of these classes of drugs in the NT-proBNP-
guided group was substantially less in this study (55% for
ACE/ARB and 48% for β-blockers at 12 months, Table 2).
Whether the lack of up-titration ofmedical therapy observed
in this studywas related to patient characteristics (eg, inabil-
ity to up-titrate due to azotemia or hypotension) or physician
behavior (eg, unwillingness to up-titrate due to concern over
adverse effects) in not clear from these data.
This study enrolled patients with high-risk features
(elevated natriuretic peptide levels within the prior 30 days
and an HF event within the prior 12 months) and allowed
a broad range of renal function, resulting in a study popula-
tion with relatively advanced HF compared with most other
clinical trials involving ambulatory patients with HFrEF.
By way of comparison, the median baseline NT-proBNP value
in this study (2607 pg/mL) was 1.6-fold that of patients
enrolled in the Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality andMorbidity in Heart
Failure (PARADIGM-HF) study of sacubitril/valsartan17 and
3.2-fold that of patients enrolled in the Heart Failure and a
Controlled Trial Investigating Outcomes of Exercise Training
(HF-ACTION) study.20 Patients with more severe HF such as
those in this study may have more limitations to intensifica-
tion of HF therapy, in particular hypotension and azotemia,
which may have limited this ability to aggressively up-titrate
Figure 3. Change in NT-proBNP Levels
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medical therapy in the guided-therapy group in response to
above target NT-proBNP levels.
Anotherpotential differencebetween this studyandother
datamay relate todifference in thecontrol group. In the single-
center ProBNP Outpatient Tailored Chronic HF Therapy
(PROTECT) study, patients randomized to receive biomarker-
guided therapy achieved a 44% decrease in the NT-proBNP
level over time (comparedwith a 5%decrease in theusual care
group), which was associated with a significant improvement
in clinical outcomes for those patients randomized to the
NT-proBNP-guided strategy.8 By contrast, in the current trial,
both the decrease inNT-proBNP concentrations (Figure 3) and
the proportion of patients in each group who reached the tar-
get NT-proBNP value of less than 1000 pg/mL (46% vs 40%)
were not significantly different between the groups. This sug-
gests that a key difference between this study and the
PROTECT studymay be in the usual care group rather than in
theNT-proBNP-guidedtreatmentgroup.Patientsenrolled inthe
usual caregroupof the this studyhadrelatively frequent study-
related clinic visits (median, 10visits over 15monthsof follow-
up) and adjustments to HF therapy (median, 4 adjustments),
which represents a greater intensity of care (more akin to adis-
easemanagementprogram) thanwould typically occur in rou-
tine clinical practice. Whether this frequency of clinical con-
tact affected outcomes through mechanisms other than
medication titration (eg, by earlier detection and intervention
on HF decompensation) is unknown. Although this study in-
cludedbothacademicandcommunitysites, themajorityof this
study’s sites had substantial focus and expertise in HF care,
whichmay have tended to lessen differences in the optimiza-
tionofevidence-basedHFtherapiesbetweenthestudygroups.
Limitations
This study has several important limitations. First, given the
nature of the study intervention, the study was unblinded,
whichcouldbeapotential sourceofbias.Thedesignwasbased
on an objective primary end point (cardiovascular death and
HF hospitalization) that was adjudicated by a clinical events
committee blinded to the treatment assignment in order to
mitigate this bias. Second, although the study protocol dis-
couragedmeasurement ofNT-proBNP inpatients in theusual
care group, somepatientsmayhavehadNT-proBNP levels as-
sessed at nonstudy sites or bynonstudy clinicians,whichmay
have served todiminish thedifferencebetween studygroups.
Finally, patients in both groupshadmore frequent clinical en-
counters thanwould typically occur in clinical practice,which
may have influenced the results.
Conclusions
In high-risk patients with HFrEF, a strategy of NT-proBNP-
guided therapywasnotmore effective than ausual care strat-
egy in improving outcomes.
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